Tenderwize
Zurück zur Suche

Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 250 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value or framework maximum is provided. The commercial attractiveness is unknown.

Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive discount agreements for Naltrexone (ATC N07BB04) under §130a Abs. 8 SGB V
  • Contract duration: July 1, 2025 to June 30, 2027
Vollständige Zusammenfassung anzeigen

This is an open-house model (non-procurement) for non-exclusive discount agreements on Naltrexone (ATC N07BB04) with AOK Bayern. Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and signed contract documents. The contract runs from July 1, 2025 to June 30, 2027. No estimated value is provided. The notice is published under procurement forms but is explicitly stated not to be a procurement procedure.

Risiken

No estimated value or framework maximum is provided. The commercial attractiveness is unknown.

Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Eligibility: only pharmaceutical companies may participate

Administrative

  • Submission of signed contract, annex listing covered medicines, and signed declaration of reliability
  • Documents can be submitted in paper (two originals) or electronically with qualified electronic signature

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria applicable since this is an open-house model with no selection process.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

Non-exclusive discount agreements for the active substance Naltrexone (ATC N07BB04). Eligible pharmaceutical companies can join at any time until May 5, 2027. Contracts are identical and not negotiable. Early termination possible with one-month notice. The open-house agreements automatically cease if a nationwide or regional discount contract is concluded via a formal procurement procedure.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Jun 2025 - Jun 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria applicable since this is an open-house model with no selection process.

Frist

Deadline May 05, 2027

Vergabedetails

Veröffentlichungsdatum
15 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
317360-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30